Zimberelimab was added due to the weak effect of initial therapy after 2 crucial programmed cell death-1 (PD-1) therapy biomarkers, high microsatellite instability (MSI-H) and high tumor mutational burden (TMB-H)[9] genome features, were confirmed. This evidence concerns the gene PDCD1 and neoplasm.